Correlation between hematological parameters and outcome in patients with locally advanced cervical cancer treated by concomitant chemoradiotherapy
Autor: | Annelore Barbeaux, Laurence Seidel, Christine Gennigens, Johanne Hermesse, Guy Jerusalem, Frédéric Kridelka, Adelin Albert, Frederic Forget, Marjolein De Cuypere |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2020 |
Předmět: |
0301 basic medicine
Cancer Research Time Factors Neutrophils medicine.medical_treatment Uterine Cervical Neoplasms Gastroenterology chemoradiotherapy Hemoglobins 0302 clinical medicine Leukocytes locally advanced cervical cancer Original Research Cervical cancer Aged 80 and over neutrophil Middle Aged lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens medicine.anatomical_structure Treatment Outcome Oncology 030220 oncology & carcinogenesis Carcinoma Squamous Cell Disease Progression Female white blood cell Erythrocyte Transfusion Adjuvant medicine.drug Adult medicine.medical_specialty Antineoplastic Agents Adenocarcinoma lcsh:RC254-282 03 medical and health sciences Internal medicine White blood cell medicine Humans Radiology Nuclear Medicine and imaging transfusion Aged Neoplasm Staging Retrospective Studies Cisplatin Proportional hazards model business.industry Clinical Cancer Research hemoglobin medicine.disease 030104 developmental biology Concomitant Hemoglobin Dose Fractionation Radiation Radiotherapy Intensity-Modulated Neoplasm Recurrence Local Radiotherapy Conformal business Chemoradiotherapy Biomarkers |
Zdroj: | Cancer Medicine Cancer Medicine, Vol 9, Iss 22, Pp 8432-8443 (2020) |
ISSN: | 2045-7634 |
Popis: | Background Hemoglobin (Hb), white blood cell (WBC), and polymorphonuclear neutrophil (PMN) blood counts may be correlated with outcomes in patients with locally advanced cervical cancer. Methods Hb, WBC, and PMN counts were measured at diagnosis and during concomitant cisplatin‐based chemoradiotherapy (CCRT) in a retrospective sample of 103 patients between 2010 and 2017. Red blood cell (RBC) transfusions were also recorded. The associations between hematological variables and patient overall survival (OS) and recurrence‐free survival (RFS) were assessed by Cox regression models. Results The 3‐year OS and RFS rates were 81.4% and 76.8%, respectively. In addition to tumor size and smoking, OS and RFS were found to be significantly associated with changes in WBC and PMN counts from the first to the last cisplatin cycle. Hb count throughout the treatment and RBC transfusions were not predictive of outcome. Conclusions This study found no association between Hb count or RBC transfusions and outcome. The daily practice of maintaining the Hb count above 12 g/dL during CCRT should be weighed against the potential risks of transfusions. Drops in WBC and PMN counts during treatment positively impacted OS and RFS and could, therefore, serve as biomarkers during CCRT to adapt the follow‐up and consider the need for adjuvant systemic treatments. In patients with locally advanced cervical cancer. Daily practice of maintaining the Hb count above 12 g/dL during CCRT should be weighed against potential risks of transfusions. Drops in WBC and PMN counts during treatment positively impacted OS and RFS |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |